1. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Issue 9 (September 2019) Authors: Saura, Cristina; Hlauschek, Dominik; Oliveira, Mafalda; Zardavas, Dimitrios; Jallitsch-Halper, Anita; de la Peña, Lorena; Nuciforo, Paolo; Ballestrero, Alberto; Dubsky, Peter; Lombard, Janine M; Vuylsteke, Peter; Castaneda, Carlos A; Colleoni, Marco; Santos Borges, Giuliano; Ciruelos, Eva; Fornie... Journal: Lancet oncology Issue: Volume 20:Issue 9(2019) Page Start: 1226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗